Literature DB >> 16800004

The effect of reduction in cross-validation intervals on the performance of multifactor dimensionality reduction.

Alison A Motsinger1, Marylyn D Ritchie.   

Abstract

Multifactor Dimensionality Reduction (MDR) was developed to detect genetic polymorphisms that present an increased risk of disease. Cross-validation (CV) is an important part of the MDR algorithm, as it prevents over-fitting and allows the predictive ability of a model to be evaluated. CV is a computationally intensive step in the MDR algorithm. Traditionally, MDR has been implemented using 10-fold CV. In order to reduce computation time and therefore allow MDR analysis to be applied to larger datasets, we evaluated the possibility of eliminating or reducing the number of CV intervals used for analysis. We found that eliminating CV made final model selection impossible, but that reducing the number of CV intervals from ten to five caused no loss of power, thereby reducing the computation time of the algorithm by half. The validity of this reduction was confirmed with data from an Alzheimer's disease (AD) study. Copyright (c) 2006 Wiley-Liss, Inc.

Entities:  

Mesh:

Year:  2006        PMID: 16800004     DOI: 10.1002/gepi.20166

Source DB:  PubMed          Journal:  Genet Epidemiol        ISSN: 0741-0395            Impact factor:   2.135


  27 in total

1.  Exploring the performance of Multifactor Dimensionality Reduction in large scale SNP studies and in the presence of genetic heterogeneity among epistatic disease models.

Authors:  Todd L Edwards; Kenneth Lewis; Digna R Velez; Scott Dudek; Marylyn D Ritchie
Journal:  Hum Hered       Date:  2008-12-15       Impact factor: 0.444

2.  A comparison of multifactor dimensionality reduction and L1-penalized regression to identify gene-gene interactions in genetic association studies.

Authors:  Stacey Winham; Chong Wang; Alison A Motsinger-Reif
Journal:  Stat Appl Genet Mol Biol       Date:  2011-01-06

3.  A general framework for formal tests of interaction after exhaustive search methods with applications to MDR and MDR-PDT.

Authors:  Todd L Edwards; Stephen D Turner; Eric S Torstenson; Scott M Dudek; Eden R Martin; Marylyn D Ritchie
Journal:  PLoS One       Date:  2010-02-23       Impact factor: 3.240

4.  A unified GMDR method for detecting gene-gene interactions in family and unrelated samples with application to nicotine dependence.

Authors:  Guo-Bo Chen; Nianjun Liu; Yann C Klimentidis; Xiaofeng Zhu; Degui Zhi; Xujing Wang; Xiang-Yang Lou
Journal:  Hum Genet       Date:  2013-09-21       Impact factor: 4.132

5.  A faster pedigree-based generalized multifactor dimensionality reduction method for detecting gene-gene interactions.

Authors:  Guo-Bo Chen; Jun Zhu; Xiang-Yang Lou
Journal:  Stat Interface       Date:  2011-01-01       Impact factor: 0.582

6.  The effect of retrospective sampling on estimates of prediction error for multifactor dimensionality reduction.

Authors:  Stacey J Winham; Alison A Motsinger-Reif
Journal:  Ann Hum Genet       Date:  2011-01       Impact factor: 1.670

7.  Lack of Association between Glutathione S-Transferase-M1, -T1, and -P1 Polymorphisms and Olanzapine-Induced Weight Gain in Korean Schizophrenic Patients.

Authors:  Young-Min Park; Heon-Jeong Lee; Seung-Gul Kang; Jung-Eun Choi; Jae-Hyuck Cho; Leen Kim
Journal:  Psychiatry Investig       Date:  2010-05-12       Impact factor: 2.505

8.  Polymorphisms in IL-1beta, vitamin D receptor Fok1, and Toll-like receptor 2 are associated with extrapulmonary tuberculosis.

Authors:  Alison A Motsinger-Reif; Paulo R Z Antas; Noffisat O Oki; Shawn Levy; Steven M Holland; Timothy R Sterling
Journal:  BMC Med Genet       Date:  2010-03-02       Impact factor: 2.103

9.  A cross-validation procedure for general pedigrees and matched odds ratio fitness metric implemented for the multifactor dimensionality reduction pedigree disequilibrium test.

Authors:  Todd L Edwards; Eric Torstensen; Scott Dudek; Eden R Martin; Marylyn D Ritchie
Journal:  Genet Epidemiol       Date:  2010-02       Impact factor: 2.135

10.  MTOR Pathway-Based Discovery of Genetic Susceptibility to L-DOPA-Induced Dyskinesia in Parkinson's Disease Patients.

Authors:  Núria Martín-Flores; Rubén Fernández-Santiago; Francesa Antonelli; Catalina Cerquera; Verónica Moreno; Maria Josep Martí; Mario Ezquerra; Cristina Malagelada
Journal:  Mol Neurobiol       Date:  2018-07-10       Impact factor: 5.590

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.